NCT01236040View on ClinicalTrials.gov

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

PHASE1CompletedINTERVENTIONAL

Enrollment

521

Participants

Timeline

Start Date

November 29, 2010

Primary Completion Date

September 6, 2011

Study Completion Date

August 20, 2012

Conditions

Influenza

Interventions

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2590066A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2592984A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2340274A

Intramuscular injection, two doses

BIOLOGICAL

GSK Biologicals' investigational vaccine GSK2340273A

Intramuscular injection, two doses

OTHER

Placebo

Intramuscular injection, two doses

Trial Locations (4)

30281

GSK Investigational Site, Stockbridge

66219

GSK Investigational Site, Lenexa

78705

GSK Investigational Site, Austin

92801

GSK Investigational Site, Anaheim

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01236040 - Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old | Biotech Hunter | Biotech Hunter